Cargando…
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of u...
Autores principales: | Ashtar, Mohannad, Tenshin, Hirofumi, Teramachi, Jumpei, Bat-Erdene, Ariunzaya, Hiasa, Masahiro, Oda, Asuka, Tanimoto, Kotaro, Shimizu, So, Higa, Yoshiki, Harada, Takeshi, Oura, Masahiro, Sogabe, Kimiko, Nakamura, Shingen, Fujii, Shiro, Sumitani, Ryohei, Miki, Hirokazu, Udaka, Kengo, Takahashi, Mamiko, Kagawa, Kumiko, Endo, Itsuro, Tanaka, Eiji, Matsumoto, Toshio, Abe, Masahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226249/ https://www.ncbi.nlm.nih.gov/pubmed/32283857 http://dx.doi.org/10.3390/cancers12040929 |
Ejemplares similares
-
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
por: Iwasa, Masami, et al.
Publicado: (2019) -
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
por: Teramachi, Jumpei, et al.
Publicado: (2020) -
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
por: Higa, Yoshiki, et al.
Publicado: (2023) -
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
por: Bat-Erdene, Ariunzaya, et al.
Publicado: (2016) -
TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression
por: Tenshin, Hirofumi, et al.
Publicado: (2022)